{"id":"tac-tc-ta-caf-cef","safety":{"commonSideEffects":[{"rate":null,"effect":"Neutropenia"},{"rate":null,"effect":"Anemia"},{"rate":null,"effect":"Thrombocytopenia"},{"rate":null,"effect":"Nausea and vomiting"},{"rate":null,"effect":"Alopecia"},{"rate":null,"effect":"Cardiotoxicity"},{"rate":null,"effect":"Mucositis"}]},"_chembl":{"chemblId":"CHEMBL4303658","moleculeType":"Small molecule","molecularWeight":"351.33"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"These are multi-drug chemotherapy combinations used in oncology. TAC (docetaxel, doxorubicin, cyclophosphamide) and its variants work through multiple mechanisms: cyclophosphamide is an alkylating agent, doxorubicin and epirubicin are anthracyclines that intercalate DNA, and docetaxel/fluorouracil are microtubule stabilizers and antimetabolites respectively. The combinations are designed to provide synergistic cytotoxic effects against rapidly dividing cancer cells.","oneSentence":"TAC/TC/TA/CAF/CEF are chemotherapy regimens combining docetaxel, doxorubicin, and cyclophosphamide with or without fluorouracil and epirubicin for cancer treatment.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T01:37:16.366Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Breast cancer (likely primary indication based on TAC regimen use)"},{"name":"Other solid tumors (specific indications unknown)"}]},"trialDetails":[{"nctId":"NCT01917578","phase":"PHASE3","title":"Study of Breast Cancer Shrinkage Modes After Neoadjuvant Chemotherapy With Whole-mount Serial Sections and Three-dimensional Pathological and MRI Reconstruction","status":"UNKNOWN","sponsor":"Shandong Cancer Hospital and Institute","startDate":"2008-08","conditions":"Breast Cancer","enrollment":4}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["1.TAC(docetaxel/doxorubicin/cyclophosphamide)","2.TC(docetaxel/cyclophosphamide)","3.TA(paclitaxel/doxorubicin)","4.CAF(fluorouracil/doxorubicin/cyclophosphamide)","5.CEF(cyclophosphamide/epirubicin//fluorouracil)"],"phase":"phase_3","status":"active","brandName":"TAC,TC,TA,CAF,CEF","genericName":"TAC,TC,TA,CAF,CEF","companyName":"Shandong Cancer Hospital and Institute","companyId":"shandong-cancer-hospital-and-institute","modality":"Small molecule","firstApprovalDate":"","aiSummary":"TAC/TC/TA/CAF/CEF are chemotherapy regimens combining docetaxel, doxorubicin, and cyclophosphamide with or without fluorouracil and epirubicin for cancer treatment. Used for Breast cancer (likely primary indication based on TAC regimen use), Other solid tumors (specific indications unknown).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}